Supernus Pharmaceuticals, Inc. Stock

Equities

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-07-22 EDT 5-day change 1st Jan Change
30 USD -0.83% Intraday chart for Supernus Pharmaceuticals, Inc. +4.42% +3.66%
Sales 2024 * 600M 826M Sales 2025 * 625M 860M Capitalization 1.65B 2.27B
Net income 2024 * 14M 19.28M Net income 2025 * -41M -56.45M EV / Sales 2024 * 2.75 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.64 x
P/E ratio 2024 *
120 x
P/E ratio 2025 *
-40.5 x
Employees 652
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.98%
More Fundamentals * Estimated data
Dynamic Chart

Latest transcript on Supernus Pharmaceuticals, Inc.

1 day-0.83%
1 week+4.42%
Current month+12.15%
1 month+10.95%
3 months+0.98%
6 months+5.60%
Current year+3.66%
More quotes
1 week
28.44
Extreme 28.44
31.00
1 month
25.55
Extreme 25.5501
31.00
Current year
25.53
Extreme 25.53
35.44
1 year
21.99
Extreme 21.99
35.44
3 years
21.99
Extreme 21.99
42.09
5 years
13.12
Extreme 13.12
42.09
10 years
7.31
Extreme 7.31
61.25
More quotes
Managers TitleAgeSince
Founder 62 05-03-29
Director of Finance/CFO 65 21-08-22
Chief Tech/Sci/R&D Officer 52 04-12-31
Members of the board TitleAgeSince
Director/Board Member 63 15-03-22
Chairman 78 05-03-29
Director/Board Member 78 10-11-15
More insiders
Date Price Change Volume
24-07-22 30 -0.83% 794,947
24-07-19 30.25 +3.95% 997,240
24-07-18 29.1 +0.52% 626,383
24-07-17 28.95 +0.03% 439,394
24-07-16 28.94 +0.73% 366,263

Delayed Quote Nasdaq, July 22, 2024 at 04:00 pm

More quotes
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
30 USD
Average target price
40.5 USD
Spread / Average Target
+35.00%
Consensus